ProsTAV, a novel blood-based test for biopsy decision management in significant prostate cancer.

Enrique Gómez GómezRoque Cano CastiñeiraJavier BurgosAlfredo Rodríguez AntolínBrian J MilesJuan Ignacio Martínez SalamancaFernando BiancoLuis FernándezIsabel CalmarzaJordi PastorRay G ButlerNuria de Pedro

Published in: The Prostate (2023)

ProsTAV®, a predictive model based on telomere analysis through TAV, could be used to increase the prediction capacity of significant PCa in patients with PSA between 3 and 10 ng/mL.

Keyphrases

prostate cancer
radical prostatectomy
ultrasound guided
decision making
fine needle aspiration